In vitro studies demonstrate that in FcγR-knockout mouse models, aPD-1 antibodies exhibit anti-tumor activities significantly higher than those without FcγR knockout, suggesting the inhibitory effects of FcγR on anti-tumor activities by binding with the Fc domain (Dahan et al., 2015; Chen et al., 2019). This evidence concerns the gene FCGR2A and neoplasm.